From:  Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study

 Baseline demographic and clinical characteristics

VariablesValues (n = 73)
Age at diagnosis, n, years (SD)70*, 43.9 (10.1)
Disease duration, n, years (SD)59*, 15.0 (7.9)
Age at initiation of SB5, n, years (SD)73, 59.6 (9.8)
Gender, n (%)

  • Female

54 (74.0)

  • Male

19 (26.0)
Body mass index, n (%)

  • < 18.5 (underweight)

1 (1.4)

  • 18.5–29.9 (normal)

59 (80.8)

  • ≥ 30 (obese)

13 (17.8)
Work status at SB5 initiation, n (%)

  • Full time

26 (35.6)

  • Part time

10 (13.7)

  • Unemployed

37 (50.7)
Tobacco use at SB5 initiation, n (%)

  • Current tobacco user

9 (12.3)

  • Ex-tobacco user

20 (27.4)

  • Non-tobacco user

44 (60.3)
Clinical status based on disease activity score, n (%, n = 41)

  • Remission

26 (63.4)

  • Low activity

5 (12.2)

  • Moderate activity

10 (24.4)

  • High activity

0
Concomitant therapy received by > 5% of the total patient population, n (%)

  • Methotrexate & methotrexate sodium

41 (56.2)

  • Leflunomide

9 (12.3)

  • Folic and folinic acid

22 (30.1)

  • HMG-CoA reductase inhibitors

7 (9.6)

  • Cyclooxygenase-2 inhibitors

9 (12.3)

  • Denosumab

5 (6.8)

  • Propionic acid derivatives

6 (8.2)
Biologic therapy prior to adalimumab, n (%)16 (21.9)
Received information on self-administration of SB5, n (%)66 (90.4)
Aware that SB5 should be removed from the refrigerator 30 min prior to injection, n (%)63 (86.3)
Aware that SB5 can be stored unrefrigerated < 25ºC for up to 28 days, n (%)51 (69.9)
Return to article view

* n differs from overall n due to incomplete data capture. HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A; SD: standard deviation